Impact of Sarcopenia on Non-Alcoholic Fatty Liver Disease
Nutrients · 10.02.2023 · 15 (4) · 891
DOI: 10.3390/nu15040891 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Nutrients, online erschienen am 10.02.2023. Verfasst von Michihiro Iwaki und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, Yokohama City University School of Medicine, Graduate School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yo…. Hauptthemen laut MEDLINE: Sarcopenia, Non-alcoholic Fatty Liver Disease, Insulin Resistance. Die Arbeit wurde bisher 61-mal zitiert (Crossref) und nennt 123 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
With the increasing incidence of non-alcoholic fatty liver disease (NAFLD) and the aging of the population, sarcopenia is attracting attention as one of the pathological conditions involved in the development and progression of NAFLD. In NAFLD, sarcopenia is closely associated with insulin resistance and results from the atrophy of skeletal muscle, an insulin target organ. In addition, inflammatory cytokines that promote skeletal muscle protein breakdown, low adiponectin levels leading to decreased insulin sensitivity, and hyperleptinemia are also involved in NAFLD pathogenesis. The presence of sarcopenia is a prognostic factor and increases the risk of mortality in patients with cirrhosis and post-treatment liver cancer. Sarcopenia, the presence of which mainly occurs due to decreased muscle mass, combined with increased visceral fat, can lead to sarcopenia-associated obesity, which increases the risk of NASH, liver fibrosis, and cardiovascular disease. In order to treat sarcopenia, it is necessary to properly evaluate sarcopenia status. Patients with high BMI, as in sarcopenic obesity, may improve with caloric restriction. However, inadequate oral intake may lead to further loss of muscle mass. Aerobic and resistance exercise should also be used appropriately.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Gastroenterology and Hepatology, Yokohama City University School of Medicine, Graduate School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama 236-0004, Japan.
ORCID-Profile: Takashi Kobayashi
Zitieren
APA
Iwaki, M., Kobayashi, T., Nogami, A., Saito, S., Nakajima, A., & Yoneda, M. (2023). Impact of Sarcopenia on Non-Alcoholic Fatty Liver Disease. Nutrients, 15(4), 891. https://doi.org/10.3390/nu15040891
Vancouver
Iwaki M, Kobayashi T, Nogami A, Saito S, Nakajima A, Yoneda M. Impact of Sarcopenia on Non-Alcoholic Fatty Liver Disease. Nutrients. 2023;15(4):891. doi:10.3390/nu15040891
BibTeX
@article{Iwaki2023,
author = {Iwaki, Michihiro and Kobayashi, Takashi and Nogami, Asako and Saito, Satoru and Nakajima, Atsushi and Yoneda, Masato},
title = {Impact of Sarcopenia on Non-Alcoholic Fatty Liver Disease},
journal = {Nutrients},
year = {2023},
volume = {15},
number = {4},
pages = {891},
doi = {10.3390/nu15040891}
}
EUVIMED